These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25698578)

  • 21. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
    Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
    Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.
    Giovannini C; Minguzzi M; Baglioni M; Fornari F; Giannone F; Ravaioli M; Cescon M; Chieco P; Bolondi L; Gramantieri L
    Oncotarget; 2014 Nov; 5(21):10607-20. PubMed ID: 25431954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
    Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z
    Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A p53-Responsive miRNA Network Promotes Cancer Cell Quiescence.
    La T; Liu GZ; Farrelly M; Cole N; Feng YC; Zhang YY; Sherwin SK; Yari H; Tabatabaee H; Yan XG; Guo ST; Liu T; Thorne RF; Jin L; Zhang XD
    Cancer Res; 2018 Dec; 78(23):6666-6679. PubMed ID: 30301840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
    Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulated miR-182 increases drug resistance in cisplatin-treated HCC cell by regulating TP53INP1.
    Qin J; Luo M; Qian H; Chen W
    Gene; 2014 Apr; 538(2):342-7. PubMed ID: 24447717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer.
    Tao J; Zhi X; Zhang X; Fu M; Huang H; Fan Y; Guan W; Zou C
    J Exp Clin Cancer Res; 2015 Nov; 34():139. PubMed ID: 26576539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
    Yang F; Li QJ; Gong ZB; Zhou L; You N; Wang S; Li XL; Li JJ; An JZ; Wang DS; He Y; Dou KF
    Technol Cancer Res Treat; 2014 Feb; 13(1):77-86. PubMed ID: 23862748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Xia H; Ooi LL; Hui KM
    Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells.
    Leotta M; Biamonte L; Raimondi L; Ronchetti D; Di Martino MT; Botta C; Leone E; Pitari MR; Neri A; Giordano A; Tagliaferri P; Tassone P; Amodio N
    J Cell Physiol; 2014 Dec; 229(12):2106-16. PubMed ID: 24819167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres.
    Ji Q; Hao X; Meng Y; Zhang M; Desano J; Fan D; Xu L
    BMC Cancer; 2008 Sep; 8():266. PubMed ID: 18803879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells.
    Yang T; Zheng ZM; Li XN; Li ZF; Wang Y; Geng YF; Bai L; Zhang XB
    Exp Biol Med (Maywood); 2013 Sep; 238(9):1024-32. PubMed ID: 23925649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
    Cui J; Zhang X; Huang G; Zhang Q; Dong J; Sun G; Meng Q; Li S
    Mol Pharm; 2019 Jan; 16(1):409-421. PubMed ID: 30481041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.
    Fornari F; Milazzo M; Chieco P; Negrini M; Marasco E; Capranico G; Mantovani V; Marinello J; Sabbioni S; Callegari E; Cescon M; Ravaioli M; Croce CM; Bolondi L; Gramantieri L
    J Pathol; 2012 Jul; 227(3):275-85. PubMed ID: 22262409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents.
    Lee JM; Heo MJ; Lee CG; Yang YM; Kim SG
    Oncotarget; 2015 Feb; 6(6):3918-31. PubMed ID: 25714015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-27b inhibition contributes to cytotoxicity in patulin-exposed HEK293 cells.
    Pillay Y; Nagiah S; Tiloke C; Phulukdaree A; Chuturgoon AA
    Toxicon; 2022 Apr; 210():58-65. PubMed ID: 35217024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.
    Zhu Z; Mu Y; Qi C; Wang J; Xi G; Guo J; Mi R; Zhao F
    Int J Mol Med; 2015 Feb; 35(2):340-8. PubMed ID: 25516145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
    Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
    Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.